Challenges and opportunities for diagnosis and treatment of rheumatoid arthritis in Latin America
Latin America (LA) is a multicultural region, with an estimate of just over 600 million inhabitants, displaying great heterogeneity among their nations. LA countries exhibit complex demographic characteristics because of the interaction of factors such as the different ethnic background of its population, a history of colonialism, and varying immigration patterns, resulting in a diversified population that differs in every country within the region .
The LA region has experienced a health transition characterized by fast and complex epidemiological changes in the past decades, combining increasing rates of non-communicable diseases and injuries, while keeping uncontrolled many existing endemic and emerging diseases.
The national health care systems within the LA area are heterogeneous in their organizational structure and complex in their operational configuration, and in the principles guiding the public and private sector roles in the provision of health care services. In LA, medical attention for rheumatoid arthritis (RA) faces a dual challenge, on one side, competes with a budget designed to fight poverty, lack of education, an increasing number of patients, and on the other hand, the demographic and epidemiological transitions; the insufficient number of rheumatologists and concentration of the workforce in large cities; an insufficient budget for education and research; and the backlog of accumulated problems characteristic of underdeveloped societies . In consequence, RA is not yet considered a public health priority for the national health care systems, Therefore, explaining why only 56 % of RA patients had access to full medical health coverage (thus often excluding biologics), only 58 % had more than 7 years of education, and 58 % were of a low/low-middle socioeconomic status .
Previous efforts has been made to overcome this situation including: the identification of barriers to health care , promoting access to a prompt diagnosis and treatment, developing algorithms according these realities , educating patients and doctors , or estimating the economic impact of the disease in the region  and, recently, setting the standards to harmonize the treatment provided to RA patients in LA, by developing a program focused in establish centers of excellence that would offer to RA patients, a better care .
Additionally, technological progress, drug development and diagnostic capabilities, advanced in the past two decades has resulted in major improvements in health outcomes for RA patients in developed countries, but the cost of these innovations including joint prostheses, access to biological medications and the lack of trained health personnel to deliver the specialized care, still puts these out of the reach of people with RA in most low and middle income countries. Education and training of health professionals also remains an unmet key priority .
Foster cooperation between different countries through existing national societies, organizations and colleges of Rheumatology and cooperating extensively with international organizations such as: EULAR, APLAR, AFLAR and ILAR.
Promote the educational activities and organize in conjunction with the national societies the Pan American Congress of Rheumatology, as well as to promote national or regional meetings and encourage publication and dissemination of the scientific proceedings of meetings.
Promote the educational activities and research of the PANLAR study groups.
Develop new channels of communication among the member societies and stimulate scientific research into all aspects of the aims of PANLAR.
Social and economic impact of RA and its relationship with health priorities.
The path in seeking medical care of patients with RA.
The importance of early diagnosis. Challenges and solutions.
Proper management of RA. What the guidelines recommend?
Access to optimal treatment. Current situation.
Education of patients with RA.
The training of allied health professionals.
The model of comprehensive care.
Challenges in LA for the implementation of an ideal model of health care center in patients with RA: are we ready to implement?
Each chapter has been developed by a Latin-American leading expert in the field in association with a group of experienced rheumatologists as coworkers, encompassing nine different countries in the region, thus reflecting the real challenges and opportunities for diagnosis and treatment of RA in LA. This review helps us to increase and improve the knowledge and approaches to this health condition in the region, thus promoting equity, quality, and efficiency of RA healthcare. The review includes not only the burden of the condition in LA but also its social, educational, and financial related aspects, furthermore, patient access to care, training of human resources, and novel approaches to models of care are analyzed.
Due to the current and future impact from RA in developing settings, health care systems need to develop coherent policies and strategies for dealing with this burden. Further epidemiological and health economics research is urgently needed  in this area and to better inform policy for dealing with RA in LA, to encourage multiple stakeholders (including funders, insurers, policy makers, educators, researchers, consumers, and health care givers) to co-operatively develop and implement efficient models of care to manage RA in developing countries.
- 1.Huggett S (2012) The Rise of Latin American Science. Research Trends http://www.researchtrends.com/category/issue-31-november-2012/. Accessed 2 July 2015.
- 2.Al Maini M, Adelowo F, Al Saleh J, Al Weshahi Y, Burmester GR, Cutolo M, Flood J, March L, McDonald-Blumer H, Pile K, Pineda C, Thorne C, Kvien TK (2014) The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. Clin Rheumatol doi:. doi:10.1007/s10067-014-2842-6 Google Scholar
- 3.Massardo L, Pons-Estel BA, Wojdyla D, Cardiel MH, Galarza-Maldonado CM, Sacnun MP, Soriano ER, Laurindo IM, Acevedo-Vásquez EM, Caballero-Uribe CV, Padilla O, Guibert-Toledano ZM, da Mota LM, Montufar RA, Lino-Pérez L, Díaz-Coto JF, Achurra-Castillo AF, Hernández JA, Esteva-Spinetti MH, Ramírez LA, Pineda C, Furst DE (2012) Early rheumatoid arthritis in Latin America. Low socioeconomic status relates to high disease activity at baseline. Arthritis care and research (Hoboken) 64(8):1135–1143. doi:10.1002/acr.21680 Google Scholar
- 4.Caballero-Uribe Carlo V (ed) (2006) Retos para el diagnóstico y Tratamiento de la Artritis Reumatoide en América Latina. Ediciones Uninorte, Colombia, p 500, 958-88252-21-0 v Google Scholar
- 6.Massardo L, Suárez-Almazor ME, Cardiel MH, Nava A, Levy RA, Laurindo I, Soriano ER, Acevedo-Vázquez E, Millan A, Pineda-Villaseñor C, Galarza-Maldonado C, Caballero-Uribe CV, Pons-Estel BA (2009) Management of patients with rheumatoid arthritis in Latin America. J Clin Rheumatol 15:203–210. doi:10.1097/RHU.0b013e3181a90cd8 CrossRefPubMedGoogle Scholar
- 7.Soriano ER, Galarza-Maldonado C, Cardiel MH, Pons-Estel BA, Massardo L, Caballero-Uribe CV, Achurra-Castillo AF, Barile-Fabris LA, Chávez-Corrales J, Díaz-Coto JF, Esteva-Spinetti MH, Guibert-Toledano M, Irazoque Palazuelos F, Keiserman MW, Lomonte AV, Mota LM, Pineda Villaseñor C, Alarcon GS (2008) Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context. Rheumatology (Oxford) 47(7):1097–1099. doi:10.1093/rheumatology/ken015a CrossRefGoogle Scholar
- 8.Santos-Moreno P, Galarza-Maldonado C, Caballero-Uribe CV, Cardiel MH, Massardo L, Soriano ER, Olano JA, Díaz Coto JF, Durán Pozo GR, da Silveira IG, de Castrejón VJ, Pérez LL, Méndez Justo CA, Montufar Guardado RA, Muños R, Elvir SM, Paredes Domínguez ER, Pons-Estel B, Ríos Acosta CR, Sandino S, Toro Gutiérrez CE, de Morales SM V, Pineda C (2015) REAL-PANLAR Project for the Implementation and Accreditation of Centers of Excellence in Rheumatoid Arthritis Throughout Latin America. J Clin Rheumatol 21:175–180. doi:10.1097/RHU.0000000000000247 PubMedCentralCrossRefPubMedGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.